Navigation Links
Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA
Date:7/1/2011

ted in patients taking monoamine oxidase inhibitors (MAOIs) or in patients who have taken MAOIs within the preceding 14 days. NUEDEXTA is contraindicated in patients with a known hypersensitivity to its components.

NUEDEXTA may cause serious side effects, including possible changes in heart rhythm. NUEDEXTA is contraindicated in patients with a prolonged QT interval, congenital long QT syndrome or a history suggestive of torsades de pointes, in patients with heart failure as well as patients with, or at risk of, complete atrioventricular (AV) block, unless the patient has an implanted pacemaker.

NUEDEXTA causes dose-dependent QTc prolongation. When initiating NUEDEXTA in patients at risk of QT prolongation and torsades de pointes, electrocardiographic (ECG) evaluation of QT interval should be conducted at baseline and 3-4 hours after the first dose.

The most common adverse reactions in patients taking NUEDEXTA are diarrhea, dizziness, cough, vomiting, weakness, swelling of feet and ankles, urinary tract infection, flu, elevated liver enzymes, and flatulence.

NUEDEXTA may cause dizziness. Precautions to reduce the risk of falls should be taken, particularly for patients with motor impairment affecting gait or a history of falls.

Patients should take NUEDEXTA exactly as prescribed. Patients should not take more than 2 capsules in a 24- hour period, make sure that there is an approximate 12-hour interval between doses, and not take a double dose after they miss a dose.

These are not all the risks from use of NUEDEXTA. For additional important safety information about NUEDEXTA, please see the full Prescribing Information at www.NUEDEXTA.com.

AVANIR™ is a trademark owned by Avanir Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners

©2011 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Forward Looking
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
4. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
5. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
7. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
8. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
9. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
10. Avanir Pharmaceuticals to Present at Three Conferences in March
11. Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015 Qiming Venture ... to Managing Partner effective immediately. William ... has lead and participated in many Qiming healthcare deals, ... in the Chinese market. Qiming, s success in healthcare ... he has distinguished himself with his outstanding advocacy and ...
(Date:7/1/2015)... 1, 2015 ExeGi Pharma, a company focused ... announced today that it has been granted a product ... Products Directorate (NNHPD) to sell Visbiome™ in ... by Professor Claudio De Simone , MD, PhD ... Professor De Simone recently signed an exclusive agreement with ...
(Date:7/1/2015)... -- According to a new market research ... (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), Viral), by ... to 2020", published by MarketsandMarkets, the Transfection Reagents and ... by 2020 with a CAGR of 7.2% from 2014 ... ables and 33 F igures ...
Breaking Medicine Technology:Qiming Announces the Promotion of William Hu to Managing Partner 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 2Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 4
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... As if ... symptom found in a significant number of women: leg pain. Northeast Houston Vein Center ... Leg pain, a symptom of venous reflux disease, is underdiagnosed and often overlooked. Many ...
(Date:7/1/2015)... ... ... Trevor L. Williams, DMD holds a Bachelor of Science degree in Biomedical Sciences ... in Microbiology. He graduated from the University of Florida College of Dentistry in 2015 ... and the Academy of General Dentistry. Dr. Williams was born in Tampa and is ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... solution provider of IBM software products, announced today that it has received trademark ... the integration, display and detailed analysis of data from multiple sources providing an ...
(Date:7/1/2015)... Raleigh, NC (PRWEB) , ... July 01, 2015 ... ... Britain’s 2013 mesothelioma compensation law has just published a top ten list they ... on the report. Click here to read it now. , ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Author Francesca Camp wasn’t always a ... her lap, so too did her support of the practice; a terrible car accident years ... her new book, “Do I Need It ? (And What if I Do?): Answers ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3Health News:Trevor L. Williams, D.M.D. Joins Enlow & Vance Dental Partners in Tampa, Florida 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2Health News:Francesca Camp’s New Book Unmasks Plastic Surgery Advice 2
... sector providers of social care services face a host ... commitment to expanding personal budgets* in social care. The ... expand personal budgets are outlined in ,The impact of ... This new booklet highlights the views of leading ...
... April 1 Anesiva, Inc. (Nasdaq: ANSV ... today announced that its consolidated financial statements for the ... Company,s annual report on Form 10-K filed with the ... a going concern qualification from its independent registered public ...
... notion that antiretrovirals can be postponed till later in ... HIV treatment before the patient,s immune system is too ... finds. , The finding may help settle a debate ... therapy can be deferred until later in the infection ...
... de C.V. (BMV: LAB) ("Genomma Lab" or "the Company") ... Medicinas y Medicamentos Nacionales,S.A.P.I., de C.V., a Mexican company. ... Genomma Lab will sell new product lines,within the categories ... others. , Genomma Lab will ...
... Inc. (NYSE Alternext: ... treatment of wounds using Altrazeal(TM) Transforming Powder Dressing, and data ... at the annual APWCA National Clinical Conference in Philadelphia, April ... presentations and with posters on display during the meeting.Renaat Van ...
... LOCAL HEALTHCARE EXECUTIVE SPEAKS IN DALLAS ON THE PATIENT ... environment in which a patient heals is critical to ... Future must change to meet that need, said ... healthcare conference in Dallas last week.Rumore addressed the national ...
Cached Medicine News:Health News:Third sector gears up to meet 2Health News:Third sector gears up to meet 3Health News:Anesiva Announces Going Concern Opinion and Nasdaq Notice 2Health News:Anesiva Announces Going Concern Opinion and Nasdaq Notice 3Health News:Starting HIV Therapy Earlier Saves Lives 2Health News:Starting HIV Therapy Earlier Saves Lives 3Health News:Genomma Lab Acquires the Mexican Company Medicinas y Medicamentos Nacionales 2Health News:Altrazeal(TM) Clinical Evidence to be Presented at The American Professional Wound Care Association (APWCA) National Clinical Conference 2009 2Health News:Altrazeal(TM) Clinical Evidence to be Presented at The American Professional Wound Care Association (APWCA) National Clinical Conference 2009 3Health News:'Patient Room of the Future' Speeds Healing 2
Our soft guedel airway is clear and has a color coded bite block. Airway has a smooth finish and is Latex Free. Recommended for single use. Non-Sterile....
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
Plastic. Economical. Single use. Non-Sterile....
Medicine Products: